{"id":"amlodipine-5-or-10-mg-oral","safety":{"commonSideEffects":[{"rate":"1.5–4%","effect":"Peripheral edema"},{"rate":"7–16%","effect":"Headache"},{"rate":"4–6%","effect":"Flushing"},{"rate":"4–5%","effect":"Fatigue"},{"rate":"1–3%","effect":"Dizziness"},{"rate":"1–4%","effect":"Palpitations"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Amlodipine is a dihydropyridine calcium channel blocker that selectively inhibits the influx of calcium ions through L-type calcium channels in the cell membrane of vascular smooth muscle and myocardium. This reduces intracellular calcium concentration, preventing smooth muscle contraction and leading to vasodilation of coronary and peripheral arteries. The result is decreased peripheral vascular resistance and reduced blood pressure, with additional anti-anginal effects through improved coronary blood flow.","oneSentence":"Amlodipine blocks calcium channels in vascular smooth muscle and cardiac tissue, causing vasodilation and reduced blood pressure.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:42:15.184Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"},{"name":"Chronic stable angina"},{"name":"Vasospastic angina (Prinzmetal's angina)"}]},"trialDetails":[{"nctId":"NCT06780865","phase":"NA","title":"Protecting Renal Function in Chronic Kidney Disease Patients with Isolated Nighttime Hypertension","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Institute of Hypertension","startDate":"2025-01-30","conditions":"Chronic Kidney Disease(CKD), Nocturnal Hypertension","enrollment":200},{"nctId":"NCT00568178","phase":"PHASE3","title":"An Extension Study Designed to Assess Effects of Losartan on Proteinuria in Pediatric Populations (MK-0954-326 AM1,EXT1(AM2))","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2007-06-01","conditions":"Proteinuria","enrollment":306},{"nctId":"NCT00170950","phase":"PHASE3","title":"Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension","status":"TERMINATED","sponsor":"Novartis","startDate":"2003-10","conditions":"Hypertension","enrollment":11506},{"nctId":"NCT05189015","phase":"PHASE4","title":"Effect of Olmesartan on Angiotensin(1-7) Levels and Vascular Functions in Diabetes and Hypertension","status":"COMPLETED","sponsor":"Seoul National University Bundang Hospital","startDate":"2021-01-01","conditions":"Angiotensin/Renin/Aldosterone Hypertension, Hypertension, Diabetes Mellitus, Type 2","enrollment":80},{"nctId":"NCT04191681","phase":"PHASE4","title":"Safety and Efficacy of ARNI After LVAD ImplanT (SEAL-IT) Study","status":"RECRUITING","sponsor":"The Cleveland Clinic","startDate":"2019-11-08","conditions":"Stage D Heart Failure","enrollment":50},{"nctId":"NCT01107743","phase":"","title":"Amlodipine/Atorvastatin (Caduet®) Drug Use Investigation (Regulatory Post Marketing Commitment Plan)","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2010-06","conditions":"Hypertension, Angina Pectoris, Hypercholesterolemia","enrollment":1291},{"nctId":"NCT02412761","phase":"NA","title":"Series of N-of-1 Crossover Trials of Antihypertensive Therapy in Adolescents With Essential Hypertension","status":"COMPLETED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2013-06","conditions":"Essential Hypertension","enrollment":42},{"nctId":"NCT00338338","phase":"PHASE4","title":"The Efficacy And Safety Of Lacidipine And Amlodipine Once-Daily Treatment In Hypertensive Adult Patients","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-11-07","conditions":"Uncomplicated Hypertension, Hypertension, Essential","enrollment":70},{"nctId":"NCT01964079","phase":"PHASE4","title":"Comparision of Blood Pressure Variability Between Amlodipine and Losartan","status":"COMPLETED","sponsor":"Wonju Severance Christian Hospital","startDate":"2013-04","conditions":"Hypertension","enrollment":144},{"nctId":"NCT01625494","phase":"PHASE3","title":"Study of Efficacy and Safety of Irbesartan/Amlodipine 4 Fixed Combination Therapy in Hypertensive Patients Uncontrolled on Irbesartan or Amlodipine Monotherapy","status":"COMPLETED","sponsor":"Sanofi","startDate":"2012-05","conditions":"Hypertension","enrollment":158},{"nctId":"NCT00797862","phase":"PHASE3","title":"Aliskiren and the Calcium Channel Blocker Amlodipine Combination as an Initial Treatment Strategy for Hypertension","status":"COMPLETED","sponsor":"Novartis","startDate":"2008-11","conditions":"Hypertension","enrollment":1254},{"nctId":"NCT00841672","phase":"PHASE3","title":"Efficacy and Safety of the Combination of Aliskiren (300 mg) and Amlodipine (10 mg) Compared to Amlodipine (10 mg) Monotherapy in Patients With Moderate to Severe Hypertension","status":"COMPLETED","sponsor":"Novartis","startDate":"2009-01","conditions":"Moderate to Severe Hypertension","enrollment":485},{"nctId":"NCT00542269","phase":"PHASE4","title":"Efficacy and Safety of Aliskiren/Ramipril/Amlodipine Compared With Ramipril/Amlodipine and Aliskiren/Amlodipine in Patients With Metabolic Syndrome","status":"TERMINATED","sponsor":"Novartis","startDate":"2008-03","conditions":"Hypertension With Metabolic Syndrome","enrollment":178},{"nctId":"NCT00700271","phase":"PHASE4","title":"Efficacy of a Combination of Amlodipine/Valsartan on 24H Blood Pressure Control With One Nocturnal or Diurnal Intake a Day","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2007-10","conditions":"Hypertension","enrollment":478},{"nctId":"NCT00446563","phase":"PHASE3","title":"Efficacy and Safety of Valsartan in Combination With Amlodipine Compared to Losartan Plus Hydrochlorothiazide in Patients With Hypertension and Left Ventricular Hypertrophy","status":"COMPLETED","sponsor":"Novartis","startDate":"2007-03","conditions":"Hypertension; Hypertrophy, Left Ventricular","enrollment":90},{"nctId":"NCT00867490","phase":"PHASE3","title":"Safety and Efficacy of Aliskiren + Hydrochlorothiazide (± Amlodipine 5 mg) in Patients With Moderate Hypertension","status":"COMPLETED","sponsor":"Novartis","startDate":"2009-03","conditions":"Hypertension","enrollment":186},{"nctId":"NCT00368277","phase":"PHASE3","title":"A Safety and Efficacy Trial of Aliskiren 150mg , 300 mg Compared to Ramipril 5mg, 10mg in the Elderly","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2006-09","conditions":"Hypertension","enrollment":901},{"nctId":"NCT00631514","phase":"PHASE4","title":"Interaction Between Antihypertensives and Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)","status":"COMPLETED","sponsor":"University of Split","startDate":"2005-01","conditions":"Hypertension","enrollment":88}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5242,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Lacidipine 4 or 6 mg (oral)"],"phase":"marketed","status":"active","brandName":"Amlodipine 5 or 10 mg(oral)","genericName":"Amlodipine 5 or 10 mg(oral)","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Amlodipine blocks calcium channels in vascular smooth muscle and cardiac tissue, causing vasodilation and reduced blood pressure. Used for Hypertension, Chronic stable angina, Vasospastic angina (Prinzmetal's angina).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}